1. ALLA AKTIER
  2. NYHETER
  3. LIPIDOR

Lipidor

Nyheter Lipidor Nyheter alla bolag

Lipidor – Announcement of short-term funding

MAR

STOCKHOLM, Sweden, 29th June 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces that financing of SEK 2 million is being provided through the divestment of holdings in the affiliated company Emollivet. A short-term loan of 1 million SEK has also been signed.

On 22nd June, it was announced that the Swedish Medical Products Agency confirmed the clinical plan for a new version of AKP02, namely AKP02G2. Lipidor continues to aim for a new Phase III study starting in 2024. The short-term financing allows for continued preclinical work and planning of the clinical study. After the summer, the intention is to start the process for a larger financing round.

A total of 274 shares in the associated company Emollivet have been sold to Cerbios-Pharma SA at a price per share of SEK 7,290. The price has been determined through an external valuation of Emollivet performed by independent advisors. The transaction provides Lipidor with 2 million SEK, and after the transaction Lipidor still owns 13% of the shares in Emollivet.

Lipidor has also entered into a loan agreement of up to 1 MSEK with the shareholder Råsunda Förvaltning AB. Interest of one and a half (1.5%) per cent per 30-day period or part thereof is calculated on the funds raised, and the loan is to be settled on 30 November.

This information is information that Lipidor is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-06-29 17:35 CEST.

For more information, please contact:

Ola Holmlund, CEO
Telephone: +46 (0) 72 50 70 369
Email: ola.holmlund@lipidor.se

The company´s Certified Adviser is Erik Penser Bank AB.

About Lipidor AB
Lipidor AB (Nasdaq First North Growth Market: LIPI) (www.lipidor.se) is a Swedish, Stockholm-based research and development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The Company develops topical medical products for the treatment of diseases such as psoriasis, acne vulgaris, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances.

Attachments
Lipidor – Announcement of short-term funding

Datum 2023-06-29, kl 17:35
Källa MFN
Bifogade filer
Lipidor – Announcement of short-term funding
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!